이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

염증성 무릎 관절염에 대한 펄스 전자기장 효과 평가

2026년 9월 21일 업데이트: The Hong Kong Polytechnic University

염증성 무릎 관절염에 대한 펄스 전자기장 효과를 평가하기 위한 이중맹검, 무작위 대조 예비 연구

This study will assess the efficacy of pulsed electromagnetic field therapy in patients with inflammatory knee osteoarthritis confirmed by MRI-detected effusion-synovitis. Fifty participants will be randomly allocated into two groups. One group will receive active PEMF therapy at a specific optimized parameter twice a week for 8 weeks, while the other group will receive sham treatment using the same device without PEMF signal. The primary outcome is the change in WOMAC pain score, and secondary outcomes include knee function, stiffness, quality of life, and MRI-quantified structural changes.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Knee osteoarthritis (KOA) is a leading cause of pain and disability, posing a significant socioeconomic burden. Current treatments often focus on pain relief with safety concerns, and no disease-modifying drugs are available. Pulsed electromagnetic field (PEMF) therapy is a non-invasive and safe physical modality with potential anti-inflammatory and analgesic effects. However, existing evidence for its efficacy in KOA is inconsistent, likely because KOA is a heterogeneous disease, and previous studies have not targeted specific subtypes. The inflammatory KOA subtype, identifiable via MRI, is the most prevalent and represents a critical target for precise intervention.

Methods This study is a double-blind, randomized, placebo-controlled pilot trial. Fifty patients with inflammatory KOA, confirmed by the presence of effusion-synovitis on MRI will be recruited. Participants will be randomly assigned to receive either active PEMF therapy at a specific, optimized parameter or sham treatment twice a week for 8 weeks. The primary outcome is the change in the WOMAC pain score at 3 months after treatment. Secondary outcomes include knee function and stiffness (WOMAC), quality of life (SF-12), and quantitatively assessed structural changes on MRI (e.g., effusion synovitis volume).

Expected Results The investigators anticipate that the group receiving active PEMF therapy will show a statistically significant and clinically important greater reduction in WOMAC pain scores compared to the sham treatment group.The investigators also expect to observe improvements in secondary outcomes, including better knee function and reduced signs of inflammation on MRI in the treatment group.

Conclusion This will be the first clinical trial to evaluate PEMF therapy specifically for the inflammatory subtype of KOA. Positive findings will provide crucial evidence for a novel, non-invasive, and precise therapeutic strategy for KOA management. This has the potential to improve patient care, alleviate the disease burden, and reduce healthcare costs.

연구 유형

중재적

등록 (추정된)

50

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

55년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Knee visual analogue scale (VAS) pain of <40 mm (0-100 mm)
  2. Effusion-synovitis or Hoffa synovitis MRI semi-quantitative score of ≥2 (used to determine inflammatory subtype KOA);
  3. Kellgren-Lawrence (KL) grade II and III
  4. Patients can listen, speak, read, and understand Chinese; understand the pilot study's requirements and are willing to cooperate with the investigator in conducting the pilot study
  5. Willing and able to provide written informed consent

Exclusion Criteria:

  1. Other inflammatory arthritis (e.g., gout, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, and seronegative spondyloarthropathy) and systemic lupus erythematosus.
  2. Participants with usual KOA interventions/ treatments
  3. History of knee trauma
  4. Contraindications to MRI
  5. Administration of intra-articular, intramuscular, and oral glucocorticoids within the last 4
  6. Pregnancy and lactation

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PEMF Therapy Intervention Patients with inflammatory KOA receive active PEMF therapy with optimized

Active Pulsed Electromagnetic Field (PEMF) Therapy Active PEMF therapy at specific optimized parameters, administered twice a week for 8 weeks

Assigned Interventions

위약 비교기: : Sham PEMF Treatment Patients with inflammatory KOA receive sham PEMF treatment (no effective elect

Sham Pulsed Electromagnetic Field (PEMF) Treatments treatment (matching device without active electromagnetic field) administered twice a week for 8 weeks

Matching device without active electromagnetic field) administered twice a week for 8 weeks

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Feasibility outcome:adherence
기간: 3 months after treatment

Adherence will be calculated as the actual number of completed exercise days relative to the prescribed total.

3 months after treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Serum Levels of Inflammatory Markers and Adipokines
기간: Baseline; 3 months after treatment

The serum concentrations of the following biomarker: Interleukin-6 (picograms per milliliter, pg/mL).

Baseline; 3 months after treatment
Western Ontario and McMaster Universities (WOMAC) pain score
기간: Baseline; 3 months after treatment

The primary outcome will be the Western Ontario and McMaster Universities (WOMAC) pain score. This scale consists of 5 questions assessing knee joint pain, each scored on a 5-point Likert scale (0 = no pain, 4 = extreme pain). The total score of the pain subscale ranges from 0 to 20, with higher scores indicating a more severe degree of pain.

Baseline; 3 months after treatment
Measurement of biomarkers on MRI images of the knee
기간: Baseline; 3 months after treatment

Cartilage defects (grades 0-4). A higher score indicates more severe pathology.

Baseline; 3 months after treatment
Ultrousound measurement
기간: Baseline, 1and 3 months after treatment

The severity of the following pathologies will be assessed via ultrasonography using semi-quantitative scoring systems: Synovitis(0-3), Osteophytes(0-3), Cartilage damage(0-3). A higher score indicates more severe pathology.

Baseline, 1and 3 months after treatment
Six-Minute Walk Distance
기간: Baseline;3 months after treatment

The total distance walked during the Six-Minute Walk Test, measured in meters (m).

Baseline;3 months after treatment
30-Second Chair Stand Test Repetitions
기간: Baseline; 3 months after treatment]

The maximum number of repetitions of rising fully from a standard-height chair without using arms, sitting back down, and fully rising again, completed within 30 seconds.

Baseline; 3 months after treatment]
Timed Up and Go Test Time
기간: Baseline; 3 months after treatment

The time required to complete the Timed Up and Go Test (rising from a chair, walking 3 meters, turning around, walking back, and sitting down), measured in seconds (s).

Baseline; 3 months after treatment
12-Item Short Form Health Survey Score
기간: Baseline; 3 months after treatment

Assesses overall health-related quality of life. This scale comprises 12 items, which are aggregated into summary scores for physical and mental health. The scores are transformed to a range of 0 to 100, with higher scores indicating better health status.

Baseline; 3 months after treatment
Patient Health Questionnaire-9 (PHQ-9) Score
기간: Baseline; 3 months after treatment

Assesses the severity of depressive symptoms. This scale consists of 9 items, each scored from 0 to 3. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.

Baseline; 3 months after treatment
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score
기간: Baseline; 3 months after treatment

Assesses the severity of knee stiffness. This subscale contains 2 items, each rated on a 5-point Likert scale (0 = none, 4 = extreme). The total subscale score ranges from 0 to 8, with higher scores indicating worse stiffness.

Baseline; 3 months after treatment
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score
기간: Baseline; 3 months after treatment

Assesses knee-related difficulty in performing daily activities. This subscale contains 17 items, each rated on a 5-point Likert scale (0 = none, 4 = extreme). The total subscale score ranges from 0 to 68, with higher scores indicating worse physical function.

Baseline; 3 months after treatment
Serum Levels of Interleukin-6
기간: Baseline; 3 months after treatment

The serum concentrations of the following biomarkers will be measured: Interleukin-6 (picograms per milliliter, pg/mL)

Baseline; 3 months after treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 15일

기본 완료 (추정된)

2028년 12월 31일

연구 완료 (추정된)

2028년 12월 31일

연구 등록 날짜

최초 제출

2025년 12월 10일

QC 기준을 충족하는 최초 제출

2026년 2월 27일

처음 게시됨 (실제)

2026년 3월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 22일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • HESEARS20231113002
  • 12231596 (기타 보조금/기금 번호: Health and Medical Research Fund)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .